Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 11/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29710660 | 0.91 | ALOX15 (0.38) | ALOX15CYP3A4CASP1CASP7SMN1; SMN2 | |
| SCHEMBL1703171 | 0.91 | ALOX15 (0.38) | ALOX15CYP3A4CASP1CASP7SMN1; SMN2 | |
| SCHEMBL7102084 | 0.91 | ALOX15 (0.38) | ALOX15CYP3A4CASP1CASP7SMN1; SMN2 | |
| SCHEMBL632646 | 0.89 | OPRM1 (0.37) | ALOX15CYP3A4CASP1CASP7SMN1; SMN2 | |
| SCHEMBL7101793 | 0.89 | OPRM1 (0.37) | ALOX15CYP3A4CASP1CASP7SMN1; SMN2 | |
| SCHEMBL8222575 | 0.86 | SIGMAR1 (0.57) | ALOX15CYP3A4CASP1CASP7SMN1; SMN2 | |
| SCHEMBL92778 | 0.82 | OPRM1 (0.45) | SMN1; SMN2OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL83658 | 0.82 | OPRL1 (0.42) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL21232438 | 0.80 | ALOX15 (0.36) | ALOX15CYP3A4CASP1CASP7SMN1; SMN2 | |
| SCHEMBL29060516 | 0.76 | OPRM1 (0.59) | SIGMAR1PDK2OPRL1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293535-A1 | ERBB/BTK INHIBITORS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-09-21 | — | — | US | disclosed |
| WO-2021254453-A1 | AMINOPYRIDINE COMPOUND | 南京明德新药研发有限公司 | 2021-12-23 | — | — | WO | disclosed |
| WO-2021223736-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2021-11-11 | — | — | WO | disclosed |
| US-20210252005-A1 | ERBB/BTK INHIBITORS | DIZAL (SHANGHAI) PHARMACEUTICAL CO., LTD. (CN) | 2021-08-19 | — | — | US | disclosed |
| US-11007198-B2 | ErbB/BTK inhibitors | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2021-05-18 | — | — | US | disclosed |
| US-20200316079-A1 | ERBB/BTK INHIBITORS | DIZAL (SHANGHAI) PHARMACEUTICAL CO., LTD. (CN) | 2020-10-08 | — | — | US | disclosed |
| WO-2019149164-A1 | ERBB/BTK INHIBITORS | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD (CN) | 2019-08-08 | — | — | WO | disclosed |
| EP-1856070-B1 | NOVEL DRUGS FOR TREATING RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-20110053926-A1 | New Pharmaceutically-Active Compounds for the Treatment of Respiratory Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| US-20100233268-A1 | POWDER FORMULATIONS FOR INHALATION CONTAINING ENANTIOMERICALLY PURE BETA-AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20080070909-A1 | ENANTIOMERICALLY PURE BETA AGONISTS, MANUFACTURING AND USE THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-03-20 | — | — | US | disclosed |
| US-20080053430-A1 | AEROSOL FORMULATION FOR THE INHALATION OF BETA AGONISTS | NOWAK MICHAEL | 2008-03-06 | — | — | US | disclosed |
| WO-2008023001-A1 | POWDER FORMULATIONS FOR INHALATION CONTAINING ENANTIOMERICALLY PURE BETA-AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008023005-A1 | AEROSOL FORMULATION FOR THE INHALATION OF BETA-AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008023003-A1 | DRUG COMBINATIONS FOR TREATING AIRWAY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008023004-A1 | SINGLE ENANTIOMER BETA AGONISTS METHOD FOR PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
| US-20080051392-A1 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | KONETZKI INGO | 2008-02-28 | — | — | US | disclosed |
| EP-1856070-A1 | NOVEL DRUGS FOR TREATING RESPIRATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006089859-A1 | NOVEL DRUGS FOR TREATING RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-31 | — | — | WO | disclosed |
| US-20060189605-A1 | NEW PHARMACEUTICALLY-ACTIVE COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233268-A1 | POWDER FORMULATIONS FOR INHALATION CONTAINING ENANTIOMERICALLY PURE BETA-AGONISTS | ADRB2, ADRB3, ADRB1 | ALOX15 2481/4885CYP3A4 509/4885CASP1 4714/4885 |
| US-20210252005-A1 | ERBB/BTK INHIBITORS | ERBB2, BTK, ERBB3 | ALOX15 4566/4885CYP3A4 3778/4885CASP1 4163/4885 |
| US-20060189605-A1 | NEW PHARMACEUTICALLY-ACTIVE COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | CFTR, SDHA, HRH1 | ALOX15 1144/4885CYP3A4 338/4885CASP1 2420/4885 |
| US-11007198-B2 | ErbB/BTK inhibitors | ERBB2, BTK, ERBB3 | ALOX15 4566/4885CYP3A4 3778/4885CASP1 4163/4885 |
| US-20080053430-A1 | AEROSOL FORMULATION FOR THE INHALATION OF BETA AGONISTS | ADRB1, ADRB2, ADRB3 | ALOX15 2962/4885CYP3A4 1522/4885CASP1 3121/4885 |
| US-20080070909-A1 | ENANTIOMERICALLY PURE BETA AGONISTS, MANUFACTURING AND USE THEREOF | ADRB1, ADRB2, ADRB3 | ALOX15 2387/4885CYP3A4 239/4885CASP1 3430/4885 |
| US-20200316079-A1 | ERBB/BTK INHIBITORS | ERBB2, BTK, ERBB3 | ALOX15 4566/4885CYP3A4 3778/4885CASP1 4163/4885 |
| US-20110053926-A1 | New Pharmaceutically-Active Compounds for the Treatment of Respiratory Diseases | CFTR, SDHA, HRH1 | ALOX15 1144/4885CYP3A4 338/4885CASP1 2420/4885 |
| US-20080051392-A1 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | CHRM2, CFTR, TPSB2 | ALOX15 2467/4885CYP3A4 363/4885CASP1 2624/4885 |
| US-20230293535-A1 | ERBB/BTK INHIBITORS | ERBB2, BTK, ERBB3 | ALOX15 4566/4885CYP3A4 3778/4885CASP1 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.